Estradiol Radioimmunoassay Without Chromatography: Procedure, Validation and Normal Values

Korenman, Stanley G.; Stevens, R. H.; Carpenter, Leslie; Robb, Marianne; Niswender, Gordon D.; Sherman, Barry M.

doi:10.1210/jcem-38-4-718

Cited by 388 publications

(117 citation statements)

References 0 publications

Supporting

Mentioning

116

Contrasting

Order By: Relevance

“…The sensitivity and intra-and interassay coefficients of variation (CV) for E 2 were 10 pg/ml, 11.2 and 9.9%. Cross-reactivity for this antibody with estrone is 3% (Korenman et al 1974). The sensitivity and intra-and interassay CV for testosterone were 0.1 ng/ml, 6.8 and 11.4%.…”

Section: Hormone Assaysmentioning

confidence: 85%

Stimulation of Sertoli cell proliferation: defining the response interval to an inhibitor of estrogen synthesis in the boar

et al. 2012

View full text Add to dashboard Cite

Sertoli cell proliferation occurs in two major waves after birth, one neonatally and another prepubertally, each contributing to final testicular size and sperm production. However, little is known about the regulation of either wave. We have previously shown that letrozole, an inhibitor of estrogen synthesis, increases Sertoli cell number and testicular size at sexual maturity in boars. These studies were conducted to determine whether letrozole affects the first or second proliferative wave. Boars were treated with letrozole during the first wave (treatment at 1, 3, and 5 weeks), less frequently (1 week of age only, or 1 and 5 weeks), on postnatal day 1, or during the second wave (weeks 11-16). Sertoli cells were enumerated in testes and estrogen concentrations were evaluated in serum and testes. Compared with vehicle controls, letrozole reduced estrogen in boars treated at weeks 1 and 5 or 1, 3, and 5, on postnatal day 1, or prepubertally. However, Sertoli cell numbers were increased only in boars treated at 1, 3, and 5 weeks of age. Neither perinatal (1 day old) nor prepubertal letrozole treatment affected Sertoli cell numbers. Hence, Sertoli cell proliferation was sensitive to letrozole only if letrozole was administered throughout the first wave, even though estrogen synthesis was effectively inhibited at all ages. These data indicate that the neonatal but not the prepubertal window of Sertoli cell proliferation is sensitive to an inhibitor of estrogen synthesis; this suggests that these two waves are differently regulated.

show abstract

Section: Hormone Assaysmentioning

confidence: 85%

Stimulation of Sertoli cell proliferation: defining the response interval to an inhibitor of estrogen synthesis in the boar

et al. 2012

View full text Add to dashboard Cite

show abstract

“…All samples were measured in duplicate in one assay (the sensitivity: 6 pg per tube; the intra-assay coefficient of variation: 5-8%; the inter-assay coefficient of variation: 7.5%). Estradiol levels in all samples were measured by RIA (Kostic et al, 2011), using the anti-estradiol serum No.244 already described (Korenman et al, 1974), also in duplicate in one assay (the sensitivity: 5 pg; the intra-assay coefficient of variation: 7.7%; the inter-assay coefficient of variation: 8.3%). For serum LH levels, all samples were measured in duplicate, in one assay (sensitivity less than 0.14 ng/mL; intra-assay coefficient of variation 4.2%; the inter-assay coefficient of variation: 6.8%), by RIA according to the manufacturer's protocol [ALPCO Diagnostic-LH (Rat) RIA] and the minimum detectable concentration has been assayed at 0.1 ng/mL (Andric et al, 2010a,b;Kostic et al, 2011).…”

Section: Extraction Of Steroids From Testicular Tissuementioning

confidence: 99%

Orally applied doxazosin disturbed testosterone homeostasis and changed the transcriptional profile of steroidogenic machinery, cAMP/cGMP signalling and adrenergic receptors in Leydig cells of adult rats

et al. 2012

View full text Add to dashboard Cite

SUMMARYDoxazosin (Doxa) is an a1-selective adrenergic receptor (ADR) antagonist widely used, alone or in combination, to treat high blood pressure, benign prostatic hyperplasia symptoms, and recently has been suggested as a potential drug for prostate cancer prevention/treatment. This study was designed to evaluate the effect of in vivo Doxa po-application, in clinically relevant dose, on: (i) steroidogenic machinery homeostasis; (ii) cAMP/cGMP signalling; (iii) transcription profile of ADR in Leydig cells of adult rats. The results showed that po-application of Doxa for once (19Doxa), or for two (29Doxa) or 10 (109Doxa) consecutive days significantly disturbed steroidogenic machinery homeostasis in Leydig cells. Doxa po-application significantly decreased circulating luteinizing hormone and androgens levels. The level of androgens in testicular interstitial fluid and that extracted from testes obtained from 19Doxa/29Doxa rats decreased, although it remained unchanged in 109Doxa rats. Similarly, the ex vivo basal androgen production followed in testes isolated from 19Doxa/29Doxa rats decreased, while remained unchanged in 109Doxa rats. Differently, ex vivo testosterone production and steroidogenic capacity of Leydig cells isolated from 19Doxa/29Doxa rats was stimulated, while 109Doxa had opposite effect. In the same cells, cAMP content/release showed similar stimulatory effect, but back to control level in Leydig cells of 109Doxa. 19Doxa/29Doxa decreased transcripts for cAMP specific phosphodiesterases Pde7b/Pde8b, whereas 109Doxa increased Pde4d. All types of treatment reduced the expression of genes encoding protein kinase A (PRKA) regulatory subunit (Prkar2b), whereas only 109Doxa stimulated catalytic subunit (Prkaca). Doxa application more affected cGMP signalling: stimulated transcription of constitutive nitric oxide synthases (Nos1, Nos3) in time-dependent manner, whereas reduced inducible Nos2. 109Doxa increased guanylyl cyclase 1 transcript and PRKG1 protein in Leydig cells. Orally applied Doxa significantly disturbed the transcriptional 'signature' of steroidogenic machinery, cAMP/cGMP signalling and ADRs and b-ADRs kinases in Leydig cells, thus giving new molecular insights into the role of cAMP/cGMP/adrenalin signalling in Leydig cells homeostasis.

show abstract

“…A n t i s e r a a g a i n s t progesterone (GDN 337 [3]), testosterone (GDN 250; [2]) and estradiol-17β (GDN 244; [8]) were used in each RIA. The intra-and inter-assay coefficients of variation were 7.3% and 14.3% for progesterone, 6.3% and 7.2% for testosterone and 6.7% and 17.8% for estradiol-17β, respectively.…”

Section: Radioimmunoassay (Ria) Of Progesterone Testosterone Estradmentioning

confidence: 99%

Change in Circulating Follicle-Stimulating Hormone, Luteinizing Hormone, Immunoreactive Inhibin, Progesterone, Testosterone and Estradiol-17.BETA. in Fillies from Birth to 6 Months of Age

Nakai

Wang

Tanaka

et al. 2007

JES

View full text Add to dashboard Cite

show abstract

Estradiol Radioimmunoassay Without Chromatography: Procedure, Validation and Normal Values

Cited by 388 publications

References 0 publications

Stimulation of Sertoli cell proliferation: defining the response interval to an inhibitor of estrogen synthesis in the boar

Stimulation of Sertoli cell proliferation: defining the response interval to an inhibitor of estrogen synthesis in the boar

Orally applied doxazosin disturbed testosterone homeostasis and changed the transcriptional profile of steroidogenic machinery, cAMP/cGMP signalling and adrenergic receptors in Leydig cells of adult rats

Change in Circulating Follicle-Stimulating Hormone, Luteinizing Hormone, Immunoreactive Inhibin, Progesterone, Testosterone and Estradiol-17.BETA. in Fillies from Birth to 6 Months of Age

Contact Info

Product

Resources

About